N4-Benzoylcytosine CAS 26661-13-2 Puritas ≥99.0% Sofosbuvir Intermedia Factory Featured Image

N4-Benzoylcytosine CAS 26661-13-2 Puritas ≥99.0% Sofosbuvir Factory intermedium

Description:

Nomen: N4-Benzoylcytosine

CAS: 26661-13-2

Aspectus: Alba vel Off-White pulveris

Puritas: ≥99.0% (HPLC)

Intermedia Sofosbuvir (CAS: 1190307-88-0) in curatione Hepatitis C Viris (HCV)

High Quality, Commercial Production

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Sofosbuvir Related Intermedia:

Sofosbuvir	CAS: 1190307-88-0
N4-Benzoylcytosine	CAS: 26661-13-2
2-(triphenyl-phosphanylidene) -propionicum acidum ethyl ester	CAS: 21382-82-1
Pentafluorophenol	CAS: 771-61-9

26661-13-2 - Chemical Properties:

Nomen	N4-Benzoylcytosine
CAS Number	26661-13-2
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C11H9N3O2
M. Pondus	215.21
Density	1.33±0.10 g/cm3
Liquescens punctum	>300℃(decl.)
COA & MSDS	Praesto
Origin	Shanghai, China
Fasciae vita	XXXVI Menses si Repono Proprie
Brand	Ruifu Chemical

26661-13-2 - Formulae:

Item	Specifications
Aspectus	Alba vel Off-White pulveris
Lepidium sativum	HPLC
Puritas / Analysis Methodus	≥99.0% (HPLC)
Humor (KF)	≤0.50%
Damnum in Siccatio	≤0.50%
Residere in Ignition	≤0.50%
Cytosine	≤0.50%
Metalla gravis	≤20ppm
Test Standard	Enterprise Standard
Applicationem	Medium Sofosbuvir (CAS: 1190307-88-0)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore

commoda:

FAQ:

26661-13-2 - Periculum et Salus;

Periculosam symbola Xi - Irritant
Periculum Codes R20/22 - Inspiratione noxium et absorptum.
R36/37/38 - Irritando ad oculos, systema respiratorium et cutem.
Salus Descriptio
S26 - In contactu cum oculis, statim cum aqua multa ablue et consilium medicinae quaeras.
S36 - gere idoneos tutelae vestis.
WGK Germania 3
HS Codicis 2933599099

26661-13-2 - Applicatio:

Sofosbuvir (CAS: 1190307-88-0) medicamentum adhibitum ad hepatitis curationem C. Commendatur utendum cum aliis medicamentis (ut velpatasvir) pro genotypes primi lineae curationis HCV 1, 2; 3, 4, 5, et 6. Effectum obtinet per inhibitorem nucleotidis analogi agendi, capax specialiter inhibendi HCV NS5B (dapibus non-structuralibus 5B) RNA dependens RNA polymerasis.Oral sofosbuvir fere bene toleratur in patientibus longis hepatitis C.